![Jake Bauer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jake Bauer
Direttore/Membro del Consiglio presso
IMMUNOVANT, INC.
Patrimonio netto: 4 M $ in data 30/09/2026
Profilo
Jake Bauer is currently Chairman at Bridgebio Oncology Therapeutics, Inc. and Simcha Therapeutics, Inc. He is an Independent Director at Immunovant, Inc., Enliven Therapeutics, Inc., and Attralus, Inc. He serves as Director at Simcha Therapeutics Holding Co. LLC and Enliven Therapeutics, Inc. He is a Venture Partner at ARCH Venture Partners LLC, GSK Equity Investments Ltd., and SR One Capital Management LP.
Formerly, Mr. Bauer was Director at Phoenix Tissue Repair, Inc. from 2018 to 2022.
He was Independent Director at ARYA Sciences Acquisition Corp.
V from 2021 to 2023 and at ARYA Sciences Acquisition Corp.
II in 2020.
He was VP-Business Operations & Head-Development at Ablexis LLC from 2011 to 2014.
He served as Chief Business Officer at MyoKardia, Inc. from 2018 to 2020.
He worked as Consultant at Bristol Myers Squibb Co. from 2020 to 2021.
He was Management Consultant at Putnam Associates LLC from 2001 to 2005.
He was Principal at Zafgen, Inc., Global Blood Therapeutics, Inc., Royalty Pharma Cayman Partners LP, Endo Health Solutions, Inc., CytomX LLC, Agios Pharmaceuticals, Inc., and Third Rock Ventures LLC from 2007 to 2011.
Education includes an undergraduate degree from Duke University conferred in 2001 and an MBA from Harvard Business School conferred in 2007.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 87.372 ( 0,12% ) | 4 M $ | 30/09/2026 | |
| 30/06/2026 | 8.339 ( 0% ) | 281 691 $ | 30/09/2026 | |
-.--% | 16/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
Posizioni attive di Jake Bauer
| Società | Posizione | Inizio |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 23/02/2023 |
| IMMUNOVANT, INC. | Direttore/Membro del Consiglio | 01/04/2025 |
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Investitore di Private Equity | 01/09/2021 |
Simcha Therapeutics Holding Co. LLC
 Simcha Therapeutics Holding Co. LLC BiotechnologyHealth Technology Operates as a biotechnology company | Direttore/Membro del Consiglio | - |
Simcha Therapeutics, Inc.
 Simcha Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for cancer | Presidente | 01/01/2022 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Investitore di Private Equity | - |
ARCH Venture Partners LLC
 ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners invests in disruptive science companies located in the United States. The firm target companies operating in the fields of biotechnology and technology sectors. It provides financing for early stage capital requirements with a minimum investment size of $0.05 million and also makes co-investments. | Investitore di Private Equity | 01/01/2021 |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Direttore/Membro del Consiglio | 28/07/2021 |
Enliven Therapeutics, Inc. /US/
 Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology Engages in discovery and development of small molecule treatments for cancer | Direttore/Membro del Consiglio | 19/01/2022 |
Precedenti posizioni note di Jake Bauer
| Società | Posizione | Fine |
|---|---|---|
| ░░░░ ░░░░░░░░ ░░░░░░░░░░░ ░░░░ ░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░░ ░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Jake Bauer
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
86
Relazioni di 1° grado
25
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 25 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Endo Health Solutions, Inc.
 Endo Health Solutions, Inc. Pharmaceuticals: MajorHealth Technology Manufactures analgesics pharmaceutical products | Health Technology |
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners invests in disruptive science companies located in the United States. The firm target companies operating in the fields of biotechnology and technology sectors. It provides financing for early stage capital requirements with a minimum investment size of $0.05 million and also makes co-investments. | Finance |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Royalty Pharma Cayman Partners LP
 Royalty Pharma Cayman Partners LP Investment ManagersFinance Functions as a private equity fund | Finance |
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of cardiovascular diseases | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Finance |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It provides financing for early stage capital requirements. The firm also acts as lead investor. | Finance |
CytomX LLC
 CytomX LLC Medical SpecialtiesHealth Technology Develops protein therapeutics and integrated medical diagnostic devices | Health Technology |
Ablexis LLC
 Ablexis LLC Packaged SoftwareTechnology Services Develops next-generation platform for antibody drug discovery | Technology Services |
Putnam Associates LLC
 Putnam Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides strategic management healthcare consultancy services | Commercial Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Simcha Therapeutics Holding Co. LLC
Simcha Therapeutics Holding Co. LLC BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Phoenix Tissue Repair, Inc.
 Phoenix Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Simcha Therapeutics, Inc.
Simcha Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for cancer | Health Technology |
Immunovant, Inc.
 Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology Engages in discovery and development of small molecule treatments for cancer | Health Technology |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One invests in companies located in the United States and the United kingdom. The firm focuses on the biotechnology sector. It provides financing for early stage capital requirements. | Finance |
ARYA Sciences Acquisition Corp. II
 ARYA Sciences Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Health Technology |
ARYA Sciences Acquisition Corp. V
 ARYA Sciences Acquisition Corp. V Financial ConglomeratesFinance Operates as a blank check company | Finance |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
